-
Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
Wednesday, March 6, 2024 - 1:00pm | 300Read More...Goldman Sachs has decided to maintain its Buy rating of Gossamer Bio (NASDAQ:GOSS) and lower its price target from $9.00 to $8.00. Shares of Gossamer Bio are trading up 0.69% over the last 24 hours, at $1.46 per share. A move to $8.00 would account for a 447.95% increase from the current share...
-
Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
Wednesday, March 6, 2024 - 1:00pm | 258Read More...Piper Sandler has decided to maintain its Overweight rating of Dyne Therapeutics (NASDAQ:DYN) and raise its price target from $27.00 to $29.00. Shares of Dyne Therapeutics are trading down 0.08% over the last 24 hours, at $25.85 per share. A move to $29.00 would account for a 12.19% increase from...
-
Benchmark Maintains Buy Rating for Direct Digital Holdings: Here's What You Need To Know
Wednesday, March 6, 2024 - 1:00pm | 265Read More...Benchmark has decided to maintain its Buy rating of Direct Digital Holdings (NASDAQ:DRCT) and raise its price target from $15.00 to $30.00. Shares of Direct Digital Holdings are trading up 2.73% over the last 24 hours, at $24.49 per share. A move to $30.00 would account for a 22.5% increase from...
-
Barclays Maintains Equal-Weight Rating for Compass: Here's What You Need To Know
Tuesday, March 5, 2024 - 1:00pm | 284Read More...Barclays has decided to maintain its Equal-Weight rating of Compass (NYSE:COMP) and raise its price target from $2.50 to $4.00. Shares of Compass are trading down 1.35% over the last 24 hours, at $3.66 per share. A move to $4.00 would account for a 9.29% increase from the current share price. About...
-
HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
Tuesday, March 5, 2024 - 1:00pm | 329Read More...HC Wainwright & Co. has decided to maintain its Buy rating of Inhibikase Therapeutics (NASDAQ:IKT) and raise its price target from $27.00 to $27.00. Shares of Inhibikase Therapeutics are trading down 4.44% over the last 24 hours, at $2.15 per share. A move to $27.00 would account for a 1155.81...
-
Truist Securities Maintains Buy Rating for Dick's Sporting Goods: Here's What You Need To Know
Tuesday, March 5, 2024 - 1:00pm | 303Read More...Truist Securities has decided to maintain its Buy rating of Dick's Sporting Goods (NYSE:DKS) and raise its price target from $174.00 to $201.00. Shares of Dick's Sporting Goods are trading up 0.16% over the last 24 hours, at $180.00 per share. A move to $201.00 would account for a 11.67% increase...
-
Stifel Maintains Buy Rating for Nyxoah: Here's What You Need To Know
Tuesday, March 5, 2024 - 1:00pm | 287Read More...Stifel has decided to maintain its Buy rating of Nyxoah (NASDAQ:NYXH) and raise its price target from $10.00 to $20.00. Shares of Nyxoah are trading down 3.03% over the last 24 hours, at $15.35 per share. A move to $20.00 would account for a 30.29% increase from the current share price. About...
-
Mizuho Maintains Neutral Rating for Idacorp: Here's What You Need To Know
Tuesday, March 5, 2024 - 1:00pm | 325Read More...Mizuho has decided to maintain its Neutral rating of Idacorp (NYSE:IDA) and lower its price target from $99.00 to $88.00. Shares of Idacorp are trading up 0.0% over the last 24 hours, at $88.58 per share. A move to $88.00 would account for a 0.65% decrease from the current share price. About...
-
UBS Maintains Buy Rating for Lam Research: Here's What You Need To Know
Tuesday, March 5, 2024 - 1:00pm | 314Read More...UBS has decided to maintain its Buy rating of Lam Research (NASDAQ:LRCX) and raise its price target from $885.00 to $1130.00. Shares of Lam Research are trading down 1.16% over the last 24 hours, at $966.14 per share. A move to $1130.00 would account for a 16.96% increase from the current share...
-
Wedbush Maintains Outperform Rating for Celsius Holdings: Here's What You Need To Know
Monday, March 4, 2024 - 1:00pm | 319Read More...Wedbush has decided to maintain its Outperform rating of Celsius Holdings (NASDAQ:CELH) and raise its price target from $75.00 to $90.00. Shares of Celsius Holdings are trading up 0.92% over the last 24 hours, at $80.00 per share. A move to $90.00 would account for a 12.5% increase from the current...
-
Roth MKM Maintains Buy Rating for GEN Restaurant Gr: Here's What You Need To Know
Monday, March 4, 2024 - 1:00pm | 338Read More...Roth MKM has decided to maintain its Buy rating of GEN Restaurant Gr (NASDAQ:GENK) and lower its price target from $14.00 to $11.00. Shares of GEN Restaurant Gr are trading up 16.51% over the last 24 hours, at $8.89 per share. A move to $11.00 would account for a 23.73% increase from the current...
-
Barrington Research Maintains Outperform Rating for ICF International: Here's What You Need To Know
Monday, March 4, 2024 - 1:00pm | 298Read More...Barrington Research has decided to maintain its Outperform rating of ICF International (NASDAQ:ICFI) and raise its price target from $145.00 to $173.00. Shares of ICF International are trading up 0.0% over the last 24 hours, at $155.83 per share. A move to $173.00 would account for a 11.02%...
-
Citigroup Maintains Buy Rating for Ecovyst: Here's What You Need To Know
Monday, March 4, 2024 - 1:00pm | 305Read More...Citigroup has decided to maintain its Buy rating of Ecovyst (NYSE:ECVT) and lower its price target from $12.00 to $11.50. Shares of Ecovyst are trading up 0.0% over the last 24 hours, at $9.12 per share. A move to $11.50 would account for a 26.1% increase from the current share price. About Ecovyst...
-
BMO Capital Maintains Outperform Rating for Vistra: Here's What You Need To Know
Monday, March 4, 2024 - 1:00pm | 303Read More...BMO Capital has decided to maintain its Outperform rating of Vistra (NYSE:VST) and raise its price target from $52.00 to $60.00. Shares of Vistra are trading up 1.47% over the last 24 hours, at $55.30 per share. A move to $60.00 would account for a 8.5% increase from the current share price. About...
-
Scotiabank Maintains Sector Outperform Rating for Healthpeak Properties: Here's What You Need To Know
Monday, March 4, 2024 - 1:00pm | 257Read More...Scotiabank has decided to maintain its Sector Outperform rating of Healthpeak Properties (NYSE:PEAK) and lower its price target from $23.00 to $22.00. Shares of Healthpeak Properties are trading up 0.0% over the last 24 hours, at $17.10 per share. A move to $22.00 would account for a 28.65%...







